These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15727486)

  • 1. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
    Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
    Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
    Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
    Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
    Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
    Volk J; Reinke F; van Kuilenburg AB; van Gennip AH; Schlichting C; Ganser A; Schöffski P
    Ann Oncol; 2001 Apr; 12(4):569-71. PubMed ID: 11398894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
    Braun MS; Richman SD; Quirke P; Daly C; Adlard JW; Elliott F; Barrett JH; Selby P; Meade AM; Stephens RJ; Parmar MK; Seymour MT
    J Clin Oncol; 2008 Jun; 26(16):2690-8. PubMed ID: 18509181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Rubbia-Brandt L; Giostra E; Brezault C; Roth AD; Andres A; Audard V; Sartoretti P; Dousset B; Majno PE; Soubrane O; Chaussade S; Mentha G; Terris B
    Ann Oncol; 2007 Feb; 18(2):299-304. PubMed ID: 17060484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
    Schmoll HJ
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
    Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
    Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
    Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
    Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
    Mohelnikova-Duchonova B; Melichar B; Soucek P
    World J Gastroenterol; 2014 Aug; 20(30):10316-30. PubMed ID: 25132748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
    Clin Colorectal Cancer; 2003 Feb; 2(4):205-9. PubMed ID: 12620138
    [No Abstract]   [Full Text] [Related]  

  • 13. Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
    Morelli MF; Santomaggio A; Ricevuto E; Cannita K; De Galitiis F; Tudini M; Bruera G; Mancini M; Pelliccione M; Calista F; Guglielmi F; Martella F; Lanfiuti Baldi P; Porzio G; Russo A; Gebbia N; Iacobelli S; Marchetti P; Ficorella C
    Oncol Rep; 2010 Jun; 23(6):1635-40. PubMed ID: 20428819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
    Punt CJ
    Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
    [No Abstract]   [Full Text] [Related]  

  • 16. Current approaches to first-line treatment of advanced colorectal cancer.
    Goldberg RM
    Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S9-15. PubMed ID: 15212700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
    Wicherts DA; de Haas RJ; Sebagh M; Ciacio O; Lévi F; Paule B; Giacchetti S; Guettier C; Azoulay D; Castaing D; Adam R
    Ann Surg Oncol; 2011 Mar; 18(3):659-69. PubMed ID: 20976564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
    Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
    Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
    Volovat SR; Volovat C; Negru SM; Danciu M; Scripcariu V
    J Chemother; 2016 Jun; 28(3):235-41. PubMed ID: 26018108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.